Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.

Clear filters
ClinicalTrials.gov public records Last synced Sep 5, 2026, 5:28 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1–24 of 1,521 matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
Filters: Intervention: Discontinuation of therapy Clear all
Completed Phase 1Phase 2 Interventional Results available

A Study of BBI608 Administered With Paclitaxel in Adult Patients With Advanced Malignancies

NCT01325441
View directory record Official record
Conditions
Cancer
Interventions
BBI608, Paclitaxel
Drug
Lead sponsor
Sumitomo Pharma America, Inc.
Industry
Eligibility
18 Years and older
Enrollment
565 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2021
U.S. locations
17
States / cities
Los Angeles, California • Denver, Colorado • Indianapolis, Indiana + 14 more
Source: ClinicalTrials.gov public record
Updated Nov 14, 2023 · Synced Sep 5, 2026, 5:28 AM EDT
Recruiting Phase 1 Interventional

Tegavivint With Gemcitabine in Patients With Relapsed or Refractory Osteosarcoma

NCT07144254
View directory record Official record
Conditions
Osteosarcoma Recurrent, Osteosarcoma in Children, Relapsed Osteosarcoma, Refractory Osteosarcoma
Interventions
Tegavivint, Gemcitabine
Drug
Lead sponsor
Emory University
Other
Eligibility
1 Year to 30 Years
Enrollment
24 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2028
U.S. locations
1
States / cities
Atlanta, Georgia
Source: ClinicalTrials.gov public record
Updated Jun 1, 2026 · Synced Sep 5, 2026, 5:28 AM EDT
Completed Phase 1 Interventional

First-in-Human Dose Escalation Study of XMT-1536 in Cancers Likely to Express NaPi2b

NCT06517433
View directory record Official record
Conditions
Platinum Resistant Ovarian Cancer, Non Small Cell Lung Cancer Metastatic
Interventions
upifitamab rilsodotin
Drug
Lead sponsor
Mersana Therapeutics
Industry
Eligibility
18 Years and older
Enrollment
62 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2021
U.S. locations
1
States / cities
Oklahoma City, Oklahoma
Source: ClinicalTrials.gov public record
Updated Jul 23, 2024 · Synced Sep 5, 2026, 5:28 AM EDT
Completed No phase listed Observational

Prospective Evaluation of Bleeding Risk of Anticoagulant and Anti-platelet Therapy

NCT00625248
View directory record Official record
Conditions
Bleeding
Interventions
Antithrombotics
Drug
Lead sponsor
Pain Management Center of Paducah
Other
Eligibility
18 Years and older
Enrollment
12,000 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2010
U.S. locations
1
States / cities
Paducah, Kentucky
Source: ClinicalTrials.gov public record
Updated Jun 23, 2013 · Synced Sep 5, 2026, 5:28 AM EDT
Completed Not applicable Interventional Results available

Stepping-down Approach in Patients With Chronic Poorly-controlled Diabetes on Advanced Insulin Therapy?

NCT02846233
View directory record Official record
Conditions
Type 2 Diabetes Mellitus
Interventions
GLP1 receptor agonist, basal insulin, SGLT2 inhibitor, Metformin
Drug
Lead sponsor
University of California, San Francisco
Other
Eligibility
21 Years and older
Enrollment
22 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2018
U.S. locations
1
States / cities
Fresno, California
Source: ClinicalTrials.gov public record
Updated Nov 9, 2020 · Synced Sep 5, 2026, 5:28 AM EDT
Recruiting Phase 2 Interventional

A Study of Mosunetuzumab Alone or With Zanubrutinib in People With Follicular Lymphoma

NCT05389293
View directory record Official record
Conditions
Follicular Lymphoma, Lymphoma
Interventions
Mosunetuzumab, Zanubrutinib
Drug
Lead sponsor
Memorial Sloan Kettering Cancer Center
Other
Eligibility
18 Years and older
Enrollment
152 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2027
U.S. locations
9
States / cities
Washington D.C., District of Columbia • Basking Ridge, New Jersey • Hackensack, New Jersey + 6 more
Source: ClinicalTrials.gov public record
Updated Aug 9, 2026 · Synced Sep 5, 2026, 5:28 AM EDT
Active, not recruiting Phase 1 Interventional

Study of Tuvusertib (M1774) in Combination With DNA Damage Response Inhibitor or Immune Checkpoint Inhibitor (DDRiver Solid Tumors 320)

NCT05396833
View directory record Official record
Conditions
Metastatic or Locally Advanced Unresectable Solid Tumors
Interventions
Tuvusertib, Lartesertib, Avelumab
Drug
Lead sponsor
EMD Serono Research & Development Institute, Inc.
Industry
Eligibility
18 Years and older
Enrollment
120 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2027
U.S. locations
8
States / cities
Santa Rosa, California • Miami, Florida • Augusta, Georgia + 5 more
Source: ClinicalTrials.gov public record
Updated May 27, 2026 · Synced Sep 5, 2026, 5:28 AM EDT
Completed Not applicable Interventional

Eccentric Exercise Versus Eccentric Exercise and Astym for Insertional Achilles Tendinopathy

NCT01988155
View directory record Official record
Conditions
Insertional Achilles Tendinopathy
Interventions
Eccentric Exercise, Astym
Other
Lead sponsor
Indiana University Health Ball Memorial Hospital Rehabiliation Services
Other
Eligibility
18 Years and older
Enrollment
16 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2015
U.S. locations
1
States / cities
Muncie, Indiana
Source: ClinicalTrials.gov public record
Updated Feb 22, 2016 · Synced Sep 5, 2026, 5:28 AM EDT
Completed Phase 3 Interventional Results available

Effectiveness of Ultrafiltration in Treating People With Acute Decompensated Heart Failure and Cardiorenal Syndrome (The CARRESS Study)

NCT00608491
View directory record Official record
Conditions
Heart Failure
Interventions
Stepped pharmacologic care, Ultrafiltration
Drug · Device
Lead sponsor
Duke University
Other
Eligibility
18 Years and older
Enrollment
188 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2012
U.S. locations
8
States / cities
Phoenix, Arizona • Atlanta, Georgia • Minneapolis, Minnesota + 5 more
Source: ClinicalTrials.gov public record
Updated Jun 23, 2013 · Synced Sep 5, 2026, 5:28 AM EDT
Active, not recruiting Phase 3 Interventional Results available

A Study of Ramucirumab (LY3009806) in Combination With Erlotinib in Previously Untreated Participants With EGFR Mutation-Positive Metastatic NSCLC (RELAY)

NCT02411448
View directory record Official record
Conditions
Metastatic Non-Small Cell Lung Cancer
Interventions
Ramucirumab, Placebo, Erlotinib, Gefitinib, Osimertinib
Drug
Lead sponsor
Eli Lilly and Company
Industry
Eligibility
18 Years and older
Enrollment
545 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2026
U.S. locations
7
States / cities
Los Angeles, California • Denver, Colorado • Honolulu, Hawaii + 4 more
Source: ClinicalTrials.gov public record
Updated Jan 15, 2026 · Synced Sep 5, 2026, 5:28 AM EDT
Not yet recruiting Phase 2 Interventional

Study on Treatment Outcome Patterns for Patients With CLL After Discontinuation of BTK Inhibitors

NCT07526597
View directory record Official record
Conditions
Chronic Lymphocytic Leukemia, Small Lymphocytic Lymphoma
Interventions
Discontinuing Bruton tyrosine kinase inhibitors (BTKi) therapy
Other
Lead sponsor
UNC Lineberger Comprehensive Cancer Center
Other
Eligibility
18 Years and older
Enrollment
45 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2032
U.S. locations
1
States / cities
Chapel Hill, North Carolina
Source: ClinicalTrials.gov public record
Updated Aug 4, 2026 · Synced Sep 5, 2026, 5:28 AM EDT
Terminated Phase 4 Interventional Results available

Acthar as Rescue Therapy for Transplant Glomerulopathy in Kidney Transplant Recipients

NCT02057523
View directory record Official record
Conditions
Proteinuria, Transplant Glomerulopathy
Interventions
Acthar
Drug
Lead sponsor
University of Illinois at Chicago
Other
Eligibility
18 Years to 80 Years
Enrollment
2 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2015
U.S. locations
1
States / cities
Chicago, Illinois
Source: ClinicalTrials.gov public record
Updated Sep 3, 2020 · Synced Sep 5, 2026, 5:28 AM EDT
Completed Phase 1Phase 2 Interventional Results available

A Study Evaluating Safety and Efficacy of Obinutuzumab, Polatuzumab Vedotin (Pola), and Atezolizumab (Atezo) in Participants With Relapsed or Refractory Follicular Lymphoma (FL) and Rituximab, Atezo, and Pola in Participants With Relapsed or Refractory Diffuse Large B-Cell Lymphoma (DLBCL)

NCT02729896
View directory record Official record
Conditions
Lymphoma
Interventions
Atezolizumab [TECENTRIQ], Obinutuzumab, Polatuzumab Vedotin, Rituximab
Drug
Lead sponsor
Hoffmann-La Roche
Industry
Eligibility
18 Years and older
Enrollment
36 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2019
U.S. locations
5
States / cities
Los Angeles, California • Miami, Florida • Stony Brook, New York + 2 more
Source: ClinicalTrials.gov public record
Updated Dec 22, 2020 · Synced Sep 5, 2026, 5:28 AM EDT
Completed Phase 2 Interventional Results available

Addition of Etanercept and Extracorporeal Photopheresis (ECP) to Standard Graft-Versus-Host Disease (GVHD) Prophylaxis in Stem Cell Transplant

NCT00639717
View directory record Official record
Conditions
Graft Versus Host Disease
Interventions
stem cell transplant, tacrolimus (standard GVHD prophylaxis), mycophenolate (standard GVHD prophylaxis), etanercept, methoxsalen
Procedure · Drug
Lead sponsor
University of Michigan Rogel Cancer Center
Other
Eligibility
Not listed
Enrollment
48 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2016
U.S. locations
1
States / cities
Ann Arbor, Michigan
Source: ClinicalTrials.gov public record
Updated Jul 31, 2017 · Synced Sep 5, 2026, 5:28 AM EDT
Completed Phase 1Phase 2 Interventional

Omega-3 Fatty Acids in Treating Patients With Advanced Cancer Who Have Significant Weight Loss

NCT00003077
View directory record Official record
Conditions
Leukemia, Lymphoma, Multiple Myeloma and Plasma Cell Neoplasm
Interventions
omega-3 fatty acid
Dietary Supplement
Lead sponsor
Alliance for Clinical Trials in Oncology
Other
Eligibility
18 Years to 120 Years
Enrollment
63 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
1995 – 2004
U.S. locations
5
States / cities
Wilmington, Delaware • Iowa City, Iowa • Manhasset, New York + 2 more
Source: ClinicalTrials.gov public record
Updated Jul 12, 2016 · Synced Sep 5, 2026, 5:28 AM EDT
Terminated No phase listed Observational Accepts healthy volunteers

Effect of PARP Inhibitors on Glomerular Filtration Rate

NCT04367467
View directory record Official record
Conditions
Solid Tumor, Ovarian Cancer, Breast Cancer
Interventions
Kidney Function Test
Other
Lead sponsor
University of Pennsylvania
Other
Eligibility
18 Years and older
Enrollment
2 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2020 – 2021
U.S. locations
1
States / cities
Philadelphia, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Jan 25, 2022 · Synced Sep 5, 2026, 5:28 AM EDT
Completed Not applicable Interventional

A Patch Free Treatment for Young Children With Amblyopia

NCT04086524
View directory record Official record
Conditions
Amblyopia, Binocular Vision Disorder
Interventions
Binocular cartoon treatment at home, Patching, Binocular cartoon treatment in office
Other
Lead sponsor
University of Waterloo
Other
Eligibility
36 Months to 83 Months
Enrollment
34 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2023
U.S. locations
1
States / cities
Dallas, Texas
Source: ClinicalTrials.gov public record
Updated Mar 11, 2024 · Synced Sep 5, 2026, 5:28 AM EDT
Completed Phase 2 Interventional Results available

Capecitabine and Oxaliplatin in Patients With Advanced or Metastatic Pancreatic Adenocarcinoma

NCT00585078
View directory record Official record
Conditions
Pancreatic Cancer
Interventions
Capecitabine, Oxaliplatin
Drug
Lead sponsor
Beth Israel Deaconess Medical Center
Other
Eligibility
18 Years and older
Enrollment
40 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2004 – 2011
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Apr 9, 2017 · Synced Sep 5, 2026, 5:28 AM EDT
Active, not recruiting Phase 2 Interventional

Asciminib as Initial Therapy for Patients With Chronic Myeloid Leukemia in Chronic Phase

NCT05143840
View directory record Official record
Conditions
Chronic Myeloid Leukemia, Chronic Phase, Adult CML, Leukemia, Myeloid, Leukemia,Myeloid, Chronic
Interventions
Single Agent Asciminib, Low TKI, Elective Free Treatment
Drug · Combination Product · Other
Lead sponsor
University of Alabama at Birmingham
Other
Eligibility
18 Years and older
Enrollment
100 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2032
U.S. locations
8
States / cities
Birmingham, Alabama • Atlanta, Georgia • Augusta, Georgia + 5 more
Source: ClinicalTrials.gov public record
Updated Jul 21, 2026 · Synced Sep 5, 2026, 5:28 AM EDT
Completed Phase 3 Interventional

A Study Evaluating the Safety and Tolerability of Abrupt Discontinuation of Saredutant in Patients With Depression

NCT00429260
View directory record Official record
Conditions
Depressive Disorder
Interventions
Saredutant
Drug
Lead sponsor
Sanofi
Industry
Eligibility
18 Years and older
Enrollment
125 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007
U.S. locations
1
States / cities
Malvern, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Feb 16, 2012 · Synced Sep 5, 2026, 5:28 AM EDT
Completed Phase 1 Interventional

OCR002-SP103 - Oral Immediate Release Study

NCT03846843
View directory record Official record
Conditions
Cirrhosis
Interventions
OCR-002 IR Oral Tablet, OCR-002 Oral Solution, OCR-002 IV Solution
Drug
Lead sponsor
Ocera Therapeutics, Inc.
Industry
Eligibility
18 Years to 70 Years
Enrollment
30 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2017
U.S. locations
1
States / cities
Coronado, California
Source: ClinicalTrials.gov public record
Updated Sep 19, 2021 · Synced Sep 5, 2026, 5:28 AM EDT
Recruiting Phase 2 Interventional

Open Label Trial of Oral Letermovir for CMV Prophylaxis in Thoracic Transplant Recipients

NCT06066957
View directory record Official record
Conditions
Cytomegalovirus Infections, Transplant-Related Disorder
Interventions
Letermovir 480 MG [Prevymis]
Drug
Lead sponsor
University of Pennsylvania
Other
Eligibility
18 Years and older
Enrollment
80 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2026
U.S. locations
1
States / cities
Philadelphia, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Jun 2, 2026 · Synced Sep 5, 2026, 5:28 AM EDT
Withdrawn Phase 2 Interventional

A Pilot Study to Evaluate the Efficacy and Safety of Neoadjuvant Chemoradiotherapy With Capecitabine, . . .

NCT01130701
View directory record Official record
Conditions
Pancreatic Cancer
Interventions
Neoadjuvant capecitabine, panitumumab and radiation
Other
Lead sponsor
University of Massachusetts, Worcester
Other
Eligibility
18 Years and older
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2015
U.S. locations
1
States / cities
Worcester, Massachusetts
Source: ClinicalTrials.gov public record
Updated Mar 16, 2015 · Synced Sep 5, 2026, 5:28 AM EDT
Terminated Not applicable Interventional Results available

Clinical Trial of a Computer-driven Weaning System for Patients Requiring Mechanical Ventilation

NCT00606554
View directory record Official record
Conditions
Respiratory Insufficiency
Interventions
Computer-assisted weaning program, Standard of Care weaning
Device · Behavioral
Lead sponsor
Boston Medical Center
Other
Eligibility
18 Years and older
Enrollment
33 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2010
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Dec 10, 2017 · Synced Sep 5, 2026, 5:28 AM EDT